FHTX

Foghorn Therapeutics Inc. (FHTX) - Q3 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2024. Foghorn Therapeutics is a clinical-stage biopharmaceutical company developing medicines targeting the chromatin regulatory system using its proprietary Gene Traffic Control platform. The company has no approved products and generates revenue primarily through collaboration agreements, most notably with Eli Lilly and Company.

Key Financial Metrics

Liquidity: The company holds $57.7 million in cash and cash equivalents and $209.7 million in marketable securities. Management expects these resources to fund operations for at least 12 months from the filing date.

Material Changes vs. Prior Period

• Revenue Decline: Collaboration revenue decreased significantly year-over-year. Q3 2024 revenue was $7.8 million compared to $17.5 million in Q3 2023. This is primarily due to the termination of the Merck Collaboration Agreement in late 2023, which previously contributed substantial revenue recognition. This decline was partially offset by increased revenue recognition from the Lilly Collaboration Agreement.
• Expense Reduction: Total operating expenses decreased by $2.9 million in Q3 2024 compared to Q3 2023. Research and Development (R&D) expenses fell by $1.6 million, driven by reduced personnel costs and the shutdown of the FHD-609 Phase 1 clinical trial. General and Administrative (G&A) expenses decreased by $1.3 million due to lower headcount.
• Impairment Charge: For the nine months ended September 30, 2024, the company recorded a non-cash impairment charge of $2.4 million related to the sublease of office space in Cambridge, MA. No such charge was recorded in the prior year period.
• Capital Raise: In May 2024, the company completed an offering of common stock and pre-funded warrants, raising net proceeds of $102.8 million.

Outlook, Risks, and Management Commentary

• Clinical Progress: The company is conducting a Phase 1 dose escalation study of FHD-286 for acute myeloid leukemia. In collaboration with Lilly, the Phase 1 study of FHD-909 for SMARCA4 mutated cancers dosed its first patient in October 2024.
• Cost Sharing: Following the transition of the FHD-909 program to Lilly, the company now shares 50% of development costs for this program, which are included in R&D expenses.
• Going Concern: While the company expects to remain solvent for at least 12 months, it anticipates continuing operating losses and will require additional funding through equity offerings, debt, or collaborations to sustain long-term operations.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the need for additional capital, reliance on third-party CROs/CDMOs, and the potential for further revenue declines if collaboration milestones are not met.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $267.4 million cash position against projected burn rates, especially given the 50% cost-sharing arrangement with Lilly which increases R&D outflows.
• Revenue Recognition: Confirm the timing and methodology of revenue recognition under the Lilly Collaboration Agreement, as it relies on percentage-of-completion estimates which can be volatile.
• Clinical Milestones: Monitor enrollment and safety data for the FHD-286 and FHD-909 Phase 1 trials, as these are critical for future milestone payments and partnership continuity.
• Capital Needs: Assess the likelihood and terms of future capital raises, given the company's history of losses and the competitive biotech funding environment.